UroGen Pharma/$URGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About UroGen Pharma
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Ticker
$URGN
Sector
Primary listing
Employees
253
Headquarters
Website
UroGen Pharma Metrics
BasicAdvanced
$915M
-
-$3.28
1.13
-
Price and volume
Market cap
$915M
Beta
1.13
52-week high
$21.02
52-week low
$3.42
Average daily volume
1.2M
Financial strength
Current ratio
4.14
Quick ratio
3.714
Long term debt to equity
-134.854
Total debt to equity
-136.512
Interest coverage (TTM)
-8.27%
Profitability
EBITDA (TTM)
-122.177
Gross margin (TTM)
88.54%
Net profit margin (TTM)
-164.44%
Operating margin (TTM)
-129.95%
Effective tax rate (TTM)
-2.75%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
-31.21%
Return on equity (TTM)
491.48%
Valuation
Price to revenue (TTM)
9.923
Price to book
-9.79
Price to tangible book (TTM)
-9.79
Price to free cash flow (TTM)
-7.57
Free cash flow yield (TTM)
-13.21%
Free cash flow per share (TTM)
-2.613
Growth
Revenue change (TTM)
10.85%
Earnings per share change (TTM)
5.46%
3-year revenue growth (CAGR)
17.77%
3-year earnings per share growth (CAGR)
-13.40%
What the Analysts think about UroGen Pharma
Analyst ratings (Buy, Hold, Sell) for UroGen Pharma stock.
UroGen Pharma Financial Performance
Revenues and expenses
UroGen Pharma Earnings Performance
Company profitability
UroGen Pharma News
AllArticlesVideos
3 Bullish Biotech Stocks With Explosive Growth Trends
MarketBeat·1 month ago
URGN SHAREHOLDER ALERT: BFA Law Reminds UroGen Pharma Ltd. Investors of Upcoming July 28 Class Action Deadline - Contact The Firm if You Suffered Losses
Accesswire·2 months ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in UroGen Pharma Ltd. of Class Action Lawsuit And Upcoming Deadlines - URGN
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for UroGen Pharma stock?
UroGen Pharma (URGN) has a market cap of $915M as of August 22, 2025.
What is the P/E ratio for UroGen Pharma stock?
The price to earnings (P/E) ratio for UroGen Pharma (URGN) stock is 0 as of August 22, 2025.
Does UroGen Pharma stock pay dividends?
No, UroGen Pharma (URGN) stock does not pay dividends to its shareholders as of August 22, 2025.
When is the next UroGen Pharma dividend payment date?
UroGen Pharma (URGN) stock does not pay dividends to its shareholders.
What is the beta indicator for UroGen Pharma?
UroGen Pharma (URGN) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.